Binds Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 530/388.23)
  • PD-1, a receptor for B7-4, and uses therefor
    Patent number: 7101550
    Abstract: The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: September 5, 2006
    Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLC
    Inventors: Clive Wood, Gordon J. Freeman
  • Mammalian cytokines; related reagents and methods
    Patent number: 7090847
    Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: August 15, 2006
    Assignee: Schering Corporation
    Inventors: Birgit Oppmann, Rene De Waal Malefyt, Donna M. Rennick, Robert A. Kastelein, Maria T. Wiekowski, Sergio A. Lira, Satwant K. Narula
  • Anti-interferon-? antibodies
    Patent number: 7087726
    Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: August 8, 2006
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
  • Humanization of murine antibody
    Patent number: 7087409
    Abstract: A humanized murine antibody is provided. The amino acid sequences of a light chain complementarity determining region from a mouse antibody are grafted onto a human light chain, and a heavy chain complementarity determining region from a mouse antibody are grafted onto a human antibody heavy chain to produce libraries from which a humanized murine antibody having the desired specificity is selected.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: August 8, 2006
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, III, Christoph Rader
  • Anti-PRO788 antibodies
    Patent number: 7081521
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: July 25, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Antibody against the human toll- like receptor 2 (tlr2) and uses thereof
    Patent number: 7071310
    Abstract: The present invention relates to an antibody capable of binding to human TLR2 and which (i) binds only to CD14+ cells in a normal human mononuclear cell population, and not to CD14? cells; (ii) does not inhibit LPS-induced activation of normal human mononuclear cells, and to the uses thereof, for example in the treatment of bacterial infections which are mediated via the TLR2 receptor, especially bacterial sepsis. In a particular embodiment of this aspects, a utility in the treatment of Listeria infections is proposed. The antibodies also have a utility as a general research tool, for example in screening for TLR2 expression, and in the study of TLR2 function. A further aspect of the invention provides use of an agent capable of inhibiting TLR2 activation in the preparation of a composition for the treatment of Listeria infections.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: July 4, 2006
    Assignee: Leiv Eiriksson Nyskaping AS
    Inventors: Terje Espevik, Anders Sundan
  • Recombinant A2-specific TNF? specific antibodies
    Patent number: 7070775
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: July 4, 2006
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Anti-pro 1017 antibodies
    Patent number: 7067636
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 18, 2001
    Date of Patent: June 27, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Antagonists of interleukin-15
    Patent number: 7067132
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: June 27, 2006
    Assignee: Immuner Corp.
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Antibody or antibody fragments specific for a protein of the TGF-? family
    Patent number: 7067637
    Abstract: The invention provides antibody and antibody fragments which specifically bind to novel members of the TGF-? family of proteins. The TFG-? family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also applies to the production of said antibodies or antibody fragments and a diagnostic method for detecting said proteins of the TGF-? family.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: June 27, 2006
    Assignee: BioPharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
    Inventors: Gertrud Hötten, Helge Neidhardt
  • TIE-2 ligands, methods of making and uses thereof
    Patent number: 7063840
    Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: June 20, 2006
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Joanne Bruno, Mitchell Goldfarb, Thomas H. Aldrich, Peter C. Maisonpierre, Czeslaw Radziejewski, Pamela F. Jones, George D. Yancopoulos
  • Interleukin-19 antibodies
    Patent number: 7056681
    Abstract: The present invention concerns a novel human cytokine. In particular, isolated nucleic acid molecules are provided encoding interleukin-19 (IL-19). IL-19 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The IL-19 polypeptides of the present invention can also be used to raise polyclonal and monoclonal antibodies. The invention further concerns therapeutic methods for modulating cytokine production.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: June 6, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A Rosen, Joseph J Kenny
  • Endothelial-monocyte activating polypeptide III antibodies
    Patent number: 7045301
    Abstract: A human EMAP III polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating neoplasia. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: May 16, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Timothy A. Coleman, Craig A. Rosen
  • Antibodies to monocyte-colony inhibitory factor (M-CIF)
    Patent number: 7041460
    Abstract: There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine ?8 (CK?8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-? and chemokine ?1 (CK?1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: May 9, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Brent L. Kreider, Jun Zhang, Michael Antonaccio, Donna Mendrick, Pablo Jimenez, Vikram Patel, Craig A. Rosen, Mark D. Adams, Haodong Li, Steven M. Ruben
  • Antibodies against human IL-12
    Patent number: 7026456
    Abstract: The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: April 11, 2006
    Assignee: Hoffman-La Roche, Inc.
    Inventors: Maurice Kent Gately, David Howard Presky
  • Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
    Patent number: 7019119
    Abstract: A protein belonging to the TNF superfamily called TRANCE involved in signal transduction, along with nucleic acids comprising DNA sequences and degenerate variants thereof which encode TRANCE are disclosed. Modulators which are TRANCE agonists and TRANCE antagonists are also disclosed, and can be used in pharmaceutical compositions and methods disclosed herein to modulate the active life of mature dendritic cells, T cell activation, and immune response in mammal.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: March 28, 2006
    Assignee: The Rockefeller University
    Inventors: Yongwon Choi, Brian Wong, Regis Josien, Ralph Steinman
  • Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
    Patent number: 7018627
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C—C chemokine designated “Macrophage Derived Chemokine” (MDC), and polypeptide fragments and analogs thereof. Also provided are materials and methods for the recombinant or synthetic production of the chemokine, fragments, and analogs; and purified and isolated chemokine protein, and polypeptide fragments and analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing. Also provided are assays for identifying modulators of MDC chemokine activity.
    Type: Grant
    Filed: September 28, 1998
    Date of Patent: March 28, 2006
    Assignee: Icos Corporation
    Inventors: Patrick W. Gray, David H. Chantry, Michael C. Deeley, Carol J. Raport, Ronald Godiska
  • Biological products
    Patent number: 7012135
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: March 14, 2006
    Assignee: Celltech Chiroscience Limited
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Antibody fragment-peg conjugates
    Patent number: 7005504
    Abstract: Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: February 28, 2006
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Leonard Presta, Zahra Shahrokh, Gerardo Zapata
  • Antibodies to p30 polypeptides and methods making and using same
    Patent number: 6998108
    Abstract: A novel ligand (p30) for herpes virus entry mediator, HVEM, is provided. p30 is useful for modulating immune responses and in inhibiting infection by herpes virus. Methods for treating subjects with lymphoid cell disorders or those having or suspected of having a herpes virus infection, utilizing p30 of the invention, are also provided.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: February 14, 2006
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventor: Carl E. Ware
  • Antibodies directed to B7-related polypeptide, BSL-2
    Patent number: 6965018
    Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: November 15, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Glen E Mikesell, Han Chang, Robert J. Peach
  • Monoclonal antibodies against N-Terminus proBNP
    Patent number: 6960472
    Abstract: Monoclonal antibodies having high affinity for N-terminus pro brain natriuretic peptide (NT-proBNP) are described. The monoclonal antibodies are prepared against a synthetic peptide having the Sequence ID No. 1. Specifically, the monoclonal antibodies described are produced from two hybridoma cell lines, 6G11-F11-D12 and 1C3-E11-R9, deposited with the American Type Culture Collection under Accession Numbers PTA-4844 and PTA-4845 respectively. The monoclonal antibody antibodies can be used as reagents in an immunoassay system to identify blood, serum or plasma levels of NT-proBNP. Such an immunoassay system can be used for diagnosing and quantifying congestive heart failure (CHF).
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: November 1, 2005
    Assignee: Ottawa Heart Institute Research Corporation
    Inventor: Adolfo J. DeBold
  • Human antibodies against eotaxin
    Patent number: 6946546
    Abstract: Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibody VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT-213. One or more complementarity determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CDR3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: September 20, 2005
    Assignee: Cambridge Antibody Technology Limited
    Inventors: Tristan John Vaughan, Alison Jane Wilton, Stephen Smith, Sarah Helen Main
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 6946130
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: September 20, 2005
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Follistatin-3
    Patent number: 6921644
    Abstract: The present invention relates to a novel follistatin-3 protein which is a member of the family of inhibin-related proteins. In particular, isolated nucleic acid molecules are provided encoding the human follistatin-3 protein. Follistatin-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of follistatin-3 activity. Also provided are diagnostic methods for detecting reproductive system-related disorders and disorders of the regulation of cell growth and differentiation and therapeutic methods for treating reproductive system-related disorders and disorders of the regulation of cell growth and differentiation.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: July 26, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: D. Roxanne Duan, Steven M. Ruben
  • Antibodies to chemokine ?-4
    Patent number: 6921645
    Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: July 26, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Haodong Li, Mark D. Adams
  • Antibodies that bind gamma-heregulin
    Patent number: 6916624
    Abstract: A novel member of the heregulin superfamily has been identified which is designated “?-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. ?-HRG polypeptide and nucleic acid are disclosed, together with various uses therefor (e.g. use of ?-HRG nucleic acid for the recombinant production of ?-HRG). ?-HRG antagonists (e.g. neutralizing antibodies and antisense nucleic acid molecules) as well as uses therefor are also described.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: July 12, 2005
    Assignee: Genentech, Inc.
    Inventors: Gabriele Maria Schaefer, Mark Sliwkowski
  • Method for the measurement of soluble CD14 proteins separately
    Patent number: 6916628
    Abstract: The present invention provides a method for qualitative determination of low molecular weight soluble CD14 proteins separately. The present invention also provides antibodies specific to high molecular weight soluble CD14 proteins. Further, the present invention provides a measurement method for specifically determining the quality or quantity of high molecular weight soluble CD14 proteins using the antibodies with high sensitivity, simplicity and specificity.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: July 12, 2005
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Shouji Furusako, Kamon Shirakawa
  • GNK interacting amino acid decarboxylase and methods of use thereof
    Patent number: 6911336
    Abstract: The present invention discloses a novel polypeptide that contains an amino acid decarboxylase domain, and is a substrate for caspase-3. Nucleic acids that encode the novel polypeptide and antibodies to the polypeptide are also part of the present invention. Methods of using the polypeptide, the nucleic acids and antibodies are also provided.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: June 28, 2005
    Assignee: Immunex Corporation
    Inventors: Pamela M. Holland, G. Duke Virca, Timothy A. Bird, Kirsten Garka
  • Anti-IL-12 antibodies and compositions thereof
    Patent number: 6902734
    Abstract: The present invention relates to at least one anti-IL-12 antibody, including isolated nucleic acids that encode at least one anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: June 7, 2005
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Antibodies to human IL-17F and other CTLA-8-related proteins
    Patent number: 6902735
    Abstract: Polynucleotides encoding human CTLA-8 (now known as IL-17F) and related proteins are disclosed. Human CTLA-8 and related proteins, including anti-human IL-17F antibodies, and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpes CTLA-8 proteins are also provided.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: June 7, 2005
    Assignee: Genetics Institute, LLC
    Inventors: Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret M. Golden-Fleet
  • Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
    Patent number: 6896885
    Abstract: The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN® (rituximab).
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: May 24, 2005
    Assignee: Biogen Idec Inc.
    Inventor: Nabil Hanna
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 6894148
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: May 17, 2005
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood, Sherman Fong
  • Antibodies reactive to the c-terminal portion of growth factor homolog zvegf3
    Patent number: 6887982
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: May 3, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker
  • BAFF, inhibitors thereof and their use in the modulation of B-cell response
    Patent number: 6869605
    Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: March 22, 2005
    Assignee: Biogen Idec Ma Inc.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider
  • Antibodies to human chemotactic protein
    Patent number: 6867006
    Abstract: A human chemotactic polypeptide, DNA (RNA) encoding it, and a procedure for producing such a polypeptide by recombinant techniques are disclosed. Also disclosed are methods of using the polypeptide for a number of purposes, including: stem cell mobilization, myeloprotection, neuronal protection, treating tumors, wound healing, treating parasitic infection, and regulating hematopoiesis. Also disclosed are polypeptide antagonists and diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases are also disclosed.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: March 15, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Haodong Li, Steven M. Ruben, Granger Sutton, III
  • Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha
    Patent number: 6863890
    Abstract: The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathological factors and/or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient; or it comprises a combined therapy involving extracorporeal immunosorption in conjunction with the administration of an autoimmune inhibitor.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: March 8, 2005
    Assignee: Advanced Biotherapy, Inc.
    Inventors: Boris Skurkovich, Simon V. Skurkovich
  • Compositions and methods for treating hyperimmune response in the eye
    Patent number: 6861056
    Abstract: The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination with other drugs are described. Also disclosed in the invention are methods of applying a composition comprising interferon gamma antibodies topically to the eye to treat hyperimmune reactions, such as transplant rejection, uveitis, autoimmune diseases of the eye, and ocular disorders incidental to or connected with autoimmune diseases.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: March 1, 2005
    Assignee: Advanced Biotherapy, Inc.
    Inventors: Boris Skurkovich, Simon Skurkovich
  • ELISA for VEGF
    Patent number: 6855508
    Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: February 15, 2005
    Assignee: Genentech, Inc.
    Inventors: David Tai Wai Fei, Kristen Tomita
  • Monoclonal antibody inhibitor of GM-CSF, IL-3, IL-5 and other cytokines, and uses thereof
    Publication number: 20040265957
    Abstract: A method of isolating a monoclonal antibody capable of inhibiting any one of IL-3, GM-CSF and IL-5 binding to the common receptor &bgr;c, or a monoclonal antibody capable of inhibiting the cytokines binding to a receptor analogous to &bgr;c. The method includes the steps of immunising an animal with a cytokine receptor or portion of a cytokine containing the critical binding site which portion includes the extracellular domain 4 or analogous domain in the analogous common receptor or part thereof. Antibodies producing cells from the animal are then isolated and fused with a myeloma cell line and then screened for a cell line that produces an antibody of the desired type. A monoclonal antibody, or fragments thereof capable of inhibiting the binding of the cytokines IL-3, GM-CSF and IL-5 to the &bgr;c receptor, and a hybridoma cell line producing the antibody are also claimed.
    Type: Application
    Filed: February 9, 2004
    Publication date: December 30, 2004
    Inventors: Angel Lopez, Richard D'andrea
  • Modified anti-tnf aplha antibody
    Publication number: 20040260069
    Abstract: The invention relates to the modification of antibodies reactive to human tumor necrosis factor alpha (TNF alpha) to result in anti-TNF alpha antibodies that are substantially non-immunogenic or less immunogenic than any non-modified parental antibody when used in vivo. The invention relates also to peptide molecules comprising T-cell epitopes of the V-regions of the parental antibody which are modified by amino acid alteration in order to reduce or eliminate said T-cell epitopes.
    Type: Application
    Filed: May 10, 2004
    Publication date: December 23, 2004
    Inventors: Koen Hellendoorn, Matthew Baker, Francis J. Carr
  • Use of IL-12 antagonists in the treatment of rheumatoid arthritis
    Patent number: 6830751
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: December 14, 2004
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • IL-1 zeta, IL-1 zeta splice variants and Xrec2 DNAs and polypeptides
    Publication number: 20040248187
    Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
    Type: Application
    Filed: July 9, 2004
    Publication date: December 9, 2004
    Applicant: Immunex Corporation
    Inventors: John E. Sims, Dirk E. Smith, Teresa L. Born
  • Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
    Publication number: 20040247562
    Abstract: Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.
    Type: Application
    Filed: March 22, 2004
    Publication date: December 9, 2004
    Inventors: Sang Yup Lee, Nae Choon Yoo, So Young Yoo, Hyun Cheol Chung, Ki Chang Keum, Won Min Yoo, Ki Jun Jeong
  • Ilt3 and ilt4-related compositons and methods
    Publication number: 20040241167
    Abstract: This invention provides compositions which comprise at least two of a CD4+CD25+ cell, IL-10, a CD8+CD28− cell and a vitamin D3 analog. This invention also provides methods for generating a tolerogenic antigen-presenting cell, and increasing the expression of ILT3 and/or ILT4 by an antigen-presenting cell. This invention further provides methods for inhibiting the onset of or treating the rejection of an antigenic substance and inhibiting the onset of or treating an autoimmune disease in a subject. This invention further provides methods for treating and preventing AIDS, cancer, and Hepatitis C-related disorders, and for identifying agents useful for such purposes. Finally, this invention provides related compositions and kits.
    Type: Application
    Filed: June 24, 2004
    Publication date: December 2, 2004
    Inventors: Nicole Suciu-Foca, Zhuoru Liu, Chih-Chao Chang, Raffaello Cortesini
  • Compositions and methods for treatment of Severe Acute Respiratory Syndrome (SARS)
    Publication number: 20040235047
    Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
    Type: Application
    Filed: May 20, 2003
    Publication date: November 25, 2004
    Inventor: George R. Siber
  • Monoclonal antibody specific to truncated midkine (tMK) protein and uses thereof
    Publication number: 20040219614
    Abstract: The present invention relates to a monoclonal antibody or a fragment thereof specific to truncated Midkine (tMK) protein, hybridoma producing the monoclonal antibody, a method of detecting truncated Midkine protein (tMK) by use of the monoclonal antibody, a method of detecting a tumor cell, and a kit containing the monoclonal antibody for detecting truncated Midkine (tMK) protein.
    Type: Application
    Filed: May 2, 2003
    Publication date: November 4, 2004
    Inventors: Tomohiro Mitsumoto, Takao Shinozawa
  • Methods of using cytokine antagonists to treat HIV infection and AIDS
    Patent number: 6811780
    Abstract: The invention is methods of using cytokine antagonists to treat HIV. In particular, the invention is methods of treating HIV using L-4 and IL-13 cytokine antagonists, including cytokine traps and anti-IL-4 or anti-IL-13 antibodies. The invention also includes augmenting the efficacy of HIV vaccination by co-administration of the vaccine with IL-4 and IL-13 cytokine antagonists.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: November 2, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric S. Furfine, Neil Stahl
  • Compositions and methods for treating T-cell mediated autoimmune diseases
    Publication number: 20040213786
    Abstract: Methods for treating autoimmune diseases are provided. The methods utilize antibodies, antibody fragments or antigenic portions of IGIF or polynucleotides encoding each for inducing protective immunity against the T-cell mediated diseases in individuals having or being predisposed to such diseases.
    Type: Application
    Filed: January 2, 2004
    Publication date: October 28, 2004
    Applicant: Rappaport Family Institute for Research in the Medical Sciences
    Inventors: Nathan Karin, Gizi Wildbaum
  • Human monoclonal antibodies against interleukin 8 (IL-8)
    Publication number: 20040208873
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: December 16, 2003
    Publication date: October 21, 2004
    Applicants: MEDAREX, INC., GENMAB A/S
    Inventors: Jessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jorgen Petersen